search
Back to results

Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Meloxicam
NSAID
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females over the age of 18
  • The patient, if female and of reproductive potential (i.e. neither surgically sterilized nor post-menopausal), must be practicing adequate contraception (e.g. intrauterine device, contraceptive pills, Depo-Provera, or implant or double barrier device) for at least three months prior to and for the duration of their trial participation and must have a negative pregnancy test at screening. Abstinence is not considered to be an acceptable method of contraception. (It should be noted that NSAIDs might interfere with the effectiveness of intrauterine devices)
  • The patient must have a documented diagnosis of at least one of the following:

    • Osteoarthritis of the hip
    • Osteoarthritis of the knee
    • Osteoarthritis of the hand or
    • Osteoarthritis of the spine - Patients must have radiographic confirmation of the diagnosis
  • The patient is willing to change or requires a change in current prescription NSAID therapy or requires initiation of prescription NSAID therapy for treatment of OA of the hip, knee, hand or spine
  • The patient intends to remain a member of their present Managed Care Organization (MCO) for the duration of the trial
  • The patient is willing to comply with instructions and to provide written informed consent

Exclusion Criteria:

  • The patient has a known or suspected hypersensitivity to the trial drugs or their excipients, analgesics, antipyretics or NSAIDS (prescription or over-the-counter)
  • The patient has received an investigational drug or used an investigational device within 30 days prior to entering the trial
  • In the opinion of the investigator the patient has any disease or condition that may result in altered absorption, excess accumulation or impaired metabolism or excretion of the trial medication
  • The patient has a history of recurrent peptic ulcer or history (within the past 6 months) of gastrointestinal perforation, peptic ulceration documented by endoscopy or radiography, symptomatic hiatal hernia requiring daily treatment or any history of a gastrointestinal tract hemorrhage, except simple hemorrhoidal bleeding
  • The patient is currently on coumadin or might be placed on coumadin during the course of the clinical trial
  • Patients with dementia, i.e. incapable of following directions or complying with the study protocol
  • Patients with co-existing rheumatological disorders including rheumatoid arthritis
  • The patient has previously participated in this trial
  • Patients with coexisting fibromyalgia or ankylosing spondylitis
  • Patient is pregnant or lactating
  • Patient has severe hepatic failure
  • Patient has non-dialysed renal failure
  • Patient has history of GI bleed within the past 6 months
  • Patient has history of cerebrovascular bleeding or other bleeding disorders
  • Patient is receiving concomitant lithium, heparin or ticlopidine therapy
  • Patient has a history of leukopenia (White Blood Cell count < 3500/mm³)
  • The patient has a history of platelet count below the lower limit of normal or has a documented abnormal prothrombin time (PT) or partial thromboplastin time (PTT)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Meloxicam

    Usual care prescription NSAID

    Arm Description

    Outcomes

    Primary Outcome Measures

    Percentage of treatment successes and failures in patients randomized to meloxicam 7.5 mg vs.usual care prescription NSAIDs

    Secondary Outcome Measures

    Investigator's Global Assessment of Disease Activity (Likert)
    Patient's overall Assessment of pain over the past week on a visual analogue scale (VAS)
    Patient's Assessment of Health Status (VAS)
    Patient's Assessment of Satisfaction of Health
    Utility Index (VAS)
    Western Ontario and Mc Master University Osteoarthritis Index (WOMAC)
    Medication Compliance
    Disability Index
    Permanent Discontinuation of Study Medication related to lack of efficacy
    Incidence and intensity of adverse events
    Permanent Discontinuation of Study Medication related to adverse event

    Full Information

    First Posted
    July 4, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02183064
    Brief Title
    Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
    Official Title
    A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis of the Hip, Knee, Hand or Spine
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    October 1998 (undefined)
    Primary Completion Date
    November 2000 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Study to compare the percentage of treatment successes or failures in patients randomized to meloxicam 7.5 mg vs. usual care prescription NSAIDs. Additionally, health care utilization, efficacy and safety of patients in a managed healthcare setting with osteoarthritis (OA) of the hip, knee, hand or spine will be assessed.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Osteoarthritis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    1309 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Meloxicam
    Arm Type
    Experimental
    Arm Title
    Usual care prescription NSAID
    Arm Type
    Active Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Meloxicam
    Intervention Type
    Drug
    Intervention Name(s)
    NSAID
    Primary Outcome Measure Information:
    Title
    Percentage of treatment successes and failures in patients randomized to meloxicam 7.5 mg vs.usual care prescription NSAIDs
    Time Frame
    up to 6 month
    Secondary Outcome Measure Information:
    Title
    Investigator's Global Assessment of Disease Activity (Likert)
    Time Frame
    Screening (Day 0), after six month (Day 180)
    Title
    Patient's overall Assessment of pain over the past week on a visual analogue scale (VAS)
    Time Frame
    Day 0, 30, 60, 90, 120, 150, 180
    Title
    Patient's Assessment of Health Status (VAS)
    Time Frame
    Day 0, 30, 60, 90, 120, 150, 180
    Title
    Patient's Assessment of Satisfaction of Health
    Time Frame
    Day 0, 30, 60, 90, 120, 150, 180
    Title
    Utility Index (VAS)
    Time Frame
    Day 0, 30, 60, 90, 120, 150, 180
    Title
    Western Ontario and Mc Master University Osteoarthritis Index (WOMAC)
    Time Frame
    Day 0, 30, 60, 90, 120, 150, 180
    Title
    Medication Compliance
    Time Frame
    Day 30, day 180
    Title
    Disability Index
    Time Frame
    Screening (Day 0), after six month (Day 180)
    Title
    Permanent Discontinuation of Study Medication related to lack of efficacy
    Time Frame
    up to day 180
    Title
    Incidence and intensity of adverse events
    Time Frame
    from day 30 until day 180
    Title
    Permanent Discontinuation of Study Medication related to adverse event
    Time Frame
    from day 30 until day 180

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Males and females over the age of 18 The patient, if female and of reproductive potential (i.e. neither surgically sterilized nor post-menopausal), must be practicing adequate contraception (e.g. intrauterine device, contraceptive pills, Depo-Provera, or implant or double barrier device) for at least three months prior to and for the duration of their trial participation and must have a negative pregnancy test at screening. Abstinence is not considered to be an acceptable method of contraception. (It should be noted that NSAIDs might interfere with the effectiveness of intrauterine devices) The patient must have a documented diagnosis of at least one of the following: Osteoarthritis of the hip Osteoarthritis of the knee Osteoarthritis of the hand or Osteoarthritis of the spine - Patients must have radiographic confirmation of the diagnosis The patient is willing to change or requires a change in current prescription NSAID therapy or requires initiation of prescription NSAID therapy for treatment of OA of the hip, knee, hand or spine The patient intends to remain a member of their present Managed Care Organization (MCO) for the duration of the trial The patient is willing to comply with instructions and to provide written informed consent Exclusion Criteria: The patient has a known or suspected hypersensitivity to the trial drugs or their excipients, analgesics, antipyretics or NSAIDS (prescription or over-the-counter) The patient has received an investigational drug or used an investigational device within 30 days prior to entering the trial In the opinion of the investigator the patient has any disease or condition that may result in altered absorption, excess accumulation or impaired metabolism or excretion of the trial medication The patient has a history of recurrent peptic ulcer or history (within the past 6 months) of gastrointestinal perforation, peptic ulceration documented by endoscopy or radiography, symptomatic hiatal hernia requiring daily treatment or any history of a gastrointestinal tract hemorrhage, except simple hemorrhoidal bleeding The patient is currently on coumadin or might be placed on coumadin during the course of the clinical trial Patients with dementia, i.e. incapable of following directions or complying with the study protocol Patients with co-existing rheumatological disorders including rheumatoid arthritis The patient has previously participated in this trial Patients with coexisting fibromyalgia or ankylosing spondylitis Patient is pregnant or lactating Patient has severe hepatic failure Patient has non-dialysed renal failure Patient has history of GI bleed within the past 6 months Patient has history of cerebrovascular bleeding or other bleeding disorders Patient is receiving concomitant lithium, heparin or ticlopidine therapy Patient has a history of leukopenia (White Blood Cell count < 3500/mm³) The patient has a history of platelet count below the lower limit of normal or has a documented abnormal prothrombin time (PT) or partial thromboplastin time (PTT)

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.210_U01-3301.pdf
    Description
    Related Info

    Learn more about this trial

    Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis

    We'll reach out to this number within 24 hrs